Largest Reorg in FDA History Featured in Califf Senate Budget Testimony

A major agency-wide reorganization affecting regulatory affairs and medical products, and more than $12 million to tackle supply chain issues across all products areas, were included in the FDA’s FY 2025 budget proposed to a Senate Appropriations subcommittee Wednesday morning by Commissioner Robert Califf.

Addressing the Subcommittee of Agriculture, Rural Development, Food and Drug Administration and Related Agencies, Califf outlined what he labeled the FDA’s largest reorg in its history that will impact nearly half of the agency’s 18,000 employees.

Califf highlighted the agency’s priority of aggressively tackling drug and device shortages while acknowledging factors beyond its control, including manufacturing issues and delays, market failures and discontinuations. He is seeking $12.3 million to enhance the FDA’s capabilities in making supply chains more resilient, increase regulatory oversight and mitigate shortages of critical medical and food products.

View the Subcommittee hearing here.

To read the whole story, click here.

Related Topics